Elanco to buy California pet med company for $440M
The deal would boost Greenfield-based Elanco’s profile in the billion-dollar pet dermatology market and continue its acquisition strategy.
Elanco
-
Elanco shares jump after company exceeds quarterly expectations
It was the best quarter yet for Elanco since its spinoff from former parent Eli Lilly and Co. in 2018.
Read More -
Elanco cuts 50 jobs at Greenfield HQ as part of latest restructuring
The maker of animal feeds and vaccines also is closing research and development sites in Germany and New Zealand, and making smaller cuts elsewhere. Altogether, Elanco is chopping 350 jobs in 23 countries.
Read More -
Environmental work almost completed on former stamping plant property
Officials said remediation efforts are in their final stages, with final certification expected in the next few weeks. Elanco Animal Health Inc. plans to build a $100 million headquarters on the site.
Read More -
Dinner at Governor’s Residence, $25M land purchase helped snag Elanco HQ
The state’s pitch to keep Elanco Animal Health Inc. in Indiana for the long term began with a dinner at the Governor’s Residence two years ago.
Read More
Articles
Greenfield leaders hopeful city will recover from losing Elanco HQ
Elanco Animal Health Inc.’s announcement Friday that it will move its headquarters to Indianapolis came as a surprise to many business leaders in Greenfield. While disappointed, they say they are hopeful the move won’t be a significant blow to the city’s economy.
Elanco HQ expected to anchor new development, park expansion on former GM site
Beyond the public company’s $100 million headquarters campus, city and state leaders expect 26 acres to be used for an expansion of White River State Park and new projects potentially with residential, retail and office uses.
Combined state, local incentives for Elanco total at least $150M
The total doesn’t include the value of the land the state will give to Elanco Animal Health for the project. Even so, the combined city and state package is possibly the largest amount of tax breaks ever considered for an economic development deal in Indiana.
No longer sleepy and small, Elanco marks transformation with new HQ
CEO Jeff Simmons said the company’s high-profile downtown Indianapolis headquarters will signal a cultural transformation at the company, which for most of its six decades of existence operated as a little-noticed subsidiary of Eli Lilly and Co.
Elanco to build $100 million HQ campus at former GM site downtown
The state has offered at least $86 million in tax incentives, plus land for the project.
IBJ Podcast: The ambitious plan to end hunger in central Indiana
Podcast host Mason King talks with Margie Craft, a senior adviser at Elanco Animal Health who is leading Food Secure Indy, a coalition of companies, public officials and not-for-profit groups that want to coordinate hunger-relief efforts.
Elanco to cut 900 jobs in 40 countries following Bayer acquisition
The layoff is the first step in what is expected to be a major restructuring following Greenfield-based Elanco’s $6.9 billion acquisition of German conglomerate Bayer AG’s animal-health division.
Editorial: Lilly spinoff wasting no time in quest for global growth
So far, Elanco has been a textbook case for the benefits of spinoffs—for both the parent company divesting the business and the division gaining its independence.
Elanco’s big job: Making the Bayer deal work
Now that the company has closed its $6.9 billion acquisition of the German conglomerate’s animal-health division, it must now swiftly and carefully integrate the two sprawling companies in the midst of a pandemic.
Elanco gets U.S. regulatory approval for $7.6B Bayer acquisition
Shares in Elanco rose 2.8% Wednesday morning after the approval was announced, to $24.13 each.
Elanco receives European OK for $7.6B acquisition
The Greenfield-based company, which spun off from Eli Lilly and Co. in 2018, said it expects the deal to close in early August.
Lilly spin-off putting nearly 1,200 acres up for auction by Greenfield
The land formerly was owned by Eli Lilly and Co. and then was included in Elanco’s 2018 spin-off from the pharmaceutical company.
2019 YEAR IN REVIEW: Elanco strikes $7.6B deal for Bayer’s animal-health unit
The deal, which is expected to close by mid-2020, will swell Elanco from the world’s fourth-largest animal health player to the second-largest, behind only New Jersey-based Zoetis.
Elanco to reduce global workforce by 4.3%
The company is eliminating 250 jobs as part of a restructuring that’s expected to result in at least $12 million in savings in 2020.
Elanco stock sinks sharply after it announces $7.6B deal to acquire Bayer unit
Investors appeared to be nervous over the rich price of the deal and the amount of debt that Elanco will take on to finance it.
Elanco says it’s buying Bayer division for $7.6 billion
The purchase would swell Elanco from the world’s fourth-largest animal health player to the second-largest, behind only New Jersey-based Zoetis.
Elanco in advanced talks to buy Bayer animal-health unit, report says
The multibillion-dollar deal would swell the size of Elanco, which already is the fourth-largest global player in animal health.
Elanco in merger talks with pharmaceutical giant Bayer, sources say
The multibillion-dollar merger would combine Elanco, the fourth-largest global player in animal health, with Bayer’s pet-health division, which ranks fifth in veterinary medicine, Reuters reported. The combination would create a dominant force in the industry.
Elanco agrees to buy pet-drug developer for $234 million
Kansas-based Aratana Therapeutics has three treatments approved by the U.S. Food and Drug Administration and is working on drugs for a range of disease fields, including cancer.